Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
cannabinoid-therapy
Press Release
May 4, 2020
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
This is the first time a Cannabinoid-Containing Complex Mixture (CCCM™) has been awarded a U.S. patent, which thereby validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio
Read More
Press Release
Apr 6, 2020
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
GBS Global Biopharma, Inc., the Canadian holding of GB Sciences, signed an Amendment to their Agreement with the National Research Council of Canada (NRC) to include valuable testing of Mechanism of Action for its Parkinson's Disease (PD) Formulations to strengthen their Investigational New Drug (IND) Application to the US FDA in preparation for human trials addressing a $52 billion market in the US alone.
Read More
First
Prev
1
Next
Last